Experienced Medical Device Executives Join Excelsius Surgical BoardContinue reading
Author Archive: AZBio
FDA finalizes new system to identify medical devices
Rule will help to improve patient safety (FDA NEWS RELEASE)Continue reading
Linda Hunt of Dignity Health Named Arizona Bioscience Leader of the Year
Linda Hunt, President and CEO Dignity Health in Arizona to receive the 2013 Jon W. McGarity Arizona Bioscience Leader of the Year Award on October 10, 2013 at the AZBio Awards in Phoenix.Continue reading
Mayo Clinic Joins the Arizona Furnace Technology Transfer Accelerator
Mayo will add medical technology transfer expertise and intellectual property to second installation of competition.Continue reading
20 Early Stage Companies Named Recipients of the Arizona Commerce Authority AZ Fast Grant
20 EARLY STAGE COMPANIES NAMED RECIPIENTS OF THE ARIZONA COMMERCE AUTHORITY AZ FAST GRANT: Latest Round Includes New Category Supporting Arizona Manufacturing Continue reading
’Ick’ Factor Aside, Mayo Clinic Study Finds Fecal Transplants Effective
SCOTTSDALE, Ariz. – A simple treatment that involves transplanting healthy feces into a patient suffering from a debilitating and sometimes deadly infection of the colon called Clostridium difficile, or C. diff, is continuing to show significant promise, according to researchers at Mayo Clinic in Arizona.Continue reading
Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
Ventana Medical Systems, Inc., Tucson, Arizona USA. (Photo: Ventana Medical Systems, Inc.) Continue reading
NIH funding boosts new Alzheimer’s research on prevention, novel drug targets
$45 million in awards to test early interventions, explore new approaches including to the Alzheimer’s Prevention Initiative APOE4 Trial — Drs. Eric Reiman and Pierre Tariot, Banner Alzheimer’s Institute, Phoenix, and co-investigators. Fully funded in fiscal 2013 at $33.2 millionContinue reading
It’s Life in the Fast Lane for Iron Horse Dx
Iron Horse Diagnostics to receive the 2013 AZBio Fast Lane Award from the Arizona Bioindustry Association for Accelerating the Development of New ALS Diagnostic Tests.
Amyotrophic Lateral Sclerosis (also known as ALS or Lou Gehrig’s disease) is a devastating disease that is nearly always fatal within 5 years of onset. Due to similarities in their symptomatic progression is it difficult to differentiate ALS from several other disease mimics (motor neuropathy, progressive muscle atrophy, etc.) until it is too late for intervention to have any real effect. With an earlier diagnosis, and therefore earlier intervention, current clinical care may increase the lifespan of these patients and additional drug therapies that are likely to be introduced to the market could be more rapidly initiated. Not only might life expectancy increase, but patients would be given the chance for a higher quality of life for a longer duration due to more rapid inclusion of the patient into multi-disciplinary care treatment offered at specialized ALS clinics.Continue reading
MSDx Announces Issuance of First Patent for Monitoring Disease Activity in a Multiple Sclerosis Patient
TUCSON, AZ, September 17, 2013 – MSDx, Inc., a personalized medicine diagnostics company developing blood test products for monitoring disease activity in neurological disorders, announced today that the United States Patent and Trademark Office issued a patent that broadly protects the company’s exclusive rights for monitoring or detecting Multiple Sclerosis (MS) in a patient, utilizing its proprietary technology.Continue reading